COVID19 Alert Several meetings are now virtual or rescheduled Check the calendar

ADEN
Home
Upcoming Events
Past Meetings
Updates
Blog
Contact Us
Career Opportunities
Fellowships
  • Fellowships Available
  • Potential Fellows
ADEN
Home
Upcoming Events
Past Meetings
Updates
Blog
Contact Us
Career Opportunities
Fellowships
  • Fellowships Available
  • Potential Fellows
More
  • Home
  • Upcoming Events
  • Past Meetings
  • Updates
  • Blog
  • Contact Us
  • Career Opportunities
  • Fellowships
    • Fellowships Available
    • Potential Fellows
  • Home
  • Upcoming Events
  • Past Meetings
  • Updates
  • Blog
  • Contact Us
  • Career Opportunities
  • Fellowships
    • Fellowships Available
    • Potential Fellows

PSORIASIS

Most Recent Psoriasis Updates

1. Inflammation. 2023 Feb 7. doi: 10.1007/s10753-023-01785-7. Online ahead of 

print.


Human Umbilical Cord-Derived Mesenchymal Stem Cells Alleviate Psoriasis Through 

TNF-α/NF-κB/MMP13 Pathway.


Ren X(#)(1), Zhong W(#)(2), Li W(2), Tang M(1), Zhang K(2), Zhou F(3), Shi X(3), 

Wu J(3), Yu B(2), Huang C(4), Chen X(5), Zhang W(6)(7).


Author information:

(1)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical 

Research Institute, Shenzhen Peking University - the Hong Kong University of 

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province, 

China.

(2)Department of Dermatology, Peking University Shenzhen Hospital, No. 1120, 

Lianhua Road, Shenzhen, 518036, China.

(3)Department of Neurology, Peking University Shenzhen Hospital, No. 1120, 

Lianhua Road, Shenzhen, 518036, China.

(4)Department of Dermatology, Peking University Shenzhen Hospital, No. 1120, 

Lianhua Road, Shenzhen, 518036, China. conghuangphd1988@163.com.

(5)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical 

Research Institute, Shenzhen Peking University - the Hong Kong University of 

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province, 

China. littlecanva@163.com.

(6)Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical 

Research Institute, Shenzhen Peking University - the Hong Kong University of 

Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province, 

China. zhangweispace@yeah.net.

(7)Greater Bay Biomedical Innocenter, Shenzhen Bay Laboratory, Shenzhen, 

Guangdong Province, China. zhangweispace@yeah.net.

(#)Contributed equally


Psoriasis is a chronic, immune-mediated disease that affects 2-3% of the global 

population. Recently, mesenchymal stem cells (MSCs) have been used to alleviate 

psoriasis. However, the therapeutic mechanisms of MSCs remain unclear. Matrix 

metalloproteinase-13 (MMP13), a member of the MMPs family, is the key enzyme in 

the cleavage of type II collagen and plays a pivotal role in extracellular 

matrix (ECM) remodeling. Here, it was found that Mmp13 was upregulated in the 

skin lesions of an imiquimod-induced mouse model, which was downregulated after 

intravenous infusion of human umbilical cord MSCs (hUC-MSCs). Knockdown of MMP13 

inhibited the proliferation of keratinocytes and arrested the cell cycle in G1 

stage. In addition, hUC-MSCs were co-cultured with THP-1 or PMA-stimulated THP-1 

directly in vitro to simulate the fate of systematically infused hUC-MSCs. The 

level of TNF-α was decreased in the supernatant of co-cultured hUC-MSCs and 

THP-1 or PMA-stimulated THP-1. Moreover, it was identified that TNF-α 

upregulated MMP13 through the NF-κB pathway in keratinocytes. In conclusion, we 

propose that systematically infused hUC-MSCs exert a therapeutic effect on 

psoriasis through the TNF-α/NF-κB/MMP13 pathway.


© 2023. The Author(s), under exclusive licence to Springer Science+Business 

Media, LLC, part of Springer Nature.


DOI: 10.1007/s10753-023-01785-7

PMID: 36749439



2. Arch Dermatol Res. 2023 Feb 7. doi: 10.1007/s00403-023-02546-0. Online ahead of 

print.


The patient perspective on vaccine uptake in adults with psoriasis and eczema.


Noe MH(1), Archila M(2), Barbieri JS(2), Goldman N(2)(3), Lopez CG(2), 

Mostaghimi A(2), Scherer AM(4), Tan AJ(2)(5), Perez-Chada LM(2), Asgari 

MM(6)(7), Gelfand JM(8)(9).


Author information:

(1)Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. 

mnoe2@bwh.harvard.edu.

(2)Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.

(3)School of Medicine, New York Medical College, New York, NY, USA.

(4)Department of Internal Medicine, University of Iowa, Iowa, IA, USA.

(5)University of Massachusetts Medical School, Worcester, MA, USA.

(6)Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.

(7)Department of Population Medicine, Harvard Medical School, Boston, MA, USA.

(8)Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.

(9)Center for Clinical Epidemiology and Biostatistics, University of 

Pennsylvania, Philadelphia, PA, USA.


Having a chronic disease is one of the most consistent factors associated with 

vaccine uptake for adults in the general population, but vaccination beliefs and 

behaviors specific to those with chronic skin diseases have not been explored. 

The objective of this study was to explore factors associated with vaccine 

uptake and barriers to vaccination in adults with psoriasis and eczema. Virtual, 

video-based semi-structured interviews were performed with adults who 

self-reported a diagnosis of psoriasis or eczema. Interviews explored themes 

around healthcare decision making, perceived risks/benefits to vaccination, 

barriers, and vaccine knowledge. Thematic analysis was used to analyze the data. 

Of 34 study participants, 25 participants (74%) were females and 9 (26%) were 

males, with a mean age of 50.8 years (SD: 16.4, range: 24-71 yrs). Half of 

participants (n = 17) had psoriasis, and half (n = 17) had eczema. Participants 

recognized both personal and societal benefits to vaccines. Common vaccination 

barriers identified were access to appointments, concerns about side effects, 

and misinformation. Physicians, friends/family, and media, including internet 

resources, were health information resources identified by patients. These 

results summarize the unique patient perspective around vaccine uptake in adults 

with eczema and psoriasis and represent an important first step in a 

multi-pronged approach to improve vaccination rates in adults with chronic skin 

diseases.


© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 

part of Springer Nature.


DOI: 10.1007/s00403-023-02546-0

PMID: 36749390



3. J Dtsch Dermatol Ges. 2023 Feb 7. doi: 10.1111/ddg.14934. Online ahead of print.


The impact of surgical interventions on the psychosocial well-being of patients 

with hidradenitis suppurativa.


Scholl L(1), Schneider-Burrus S(2)(3), Fritz B(4), Sabat R(3)(5)(6), Bechara 

FG(1).


Author information:

(1)Department of Dermatology, Venerology, and Allergology - St. Josef-Hospital, 

Ruhr-University Bochum, Bochum, Germany.

(2)Centre for Dermatosurgery, Havelklinik, Berlin, Germany.

(3)Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical 

Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

(4)AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.

(5)Psoriasis Research and Treatment Center, Charité - Universitätsmedizin 

Berlin, Berlin, Germany.

(6)Inflammation and Regeneration of Skin, BIH Center for Regenerative Therapies, 

Charité - Universitätsmedizin Berlin, Berlin, Germany.


BACKGROUND AND OBJECTIVES: Hidradenitis suppurativa is a chronic inflammatory 

skin disease. Depending on disease severity, a combination of conservative and 

surgical treatments is necessary. This analysis aimed to determine the impact of 

surgical interventions on patient psychosocial well-being.

PATIENTS AND METHODS: This is a prospective, noninterventional, multicenter 

study. The medical history, medical examination, and patient-reported outcomes, 

including the Hospital Anxiety and Depression Scale, Dermatology Life Quality 

Index, and the Short Form-12 Health Survey, were collected from 481 patients 

with hidradenitis suppurativa.

RESULTS: Among all patients with hidradenitis suppurativa included in this 

study, 74.2% reported surgery before study inclusion, of whom 92.4% could 

identify surgery type and location. Although adjusted for confounding factors, 

such as disease severity and activity, the aforementioned patient reported 

outcomes, did not vary significantly between groups of patients with different 

techniques and number of prior surgical intervention. However, patients without 

any prior surgical intervention yielded significantly better scores.

CONCLUSIONS: In patients with hidradenitis suppurativa, previous surgery was 

associated with worse outcomes in anxiety, depression, and quality of life, 

showing the apparent need of psychological support. It remains unclear whether 

the morbidity of surgical procedures or a possible higher severity score in 

patients undergoing surgery is responsible.


© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft 

published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische 

Gesellschaft.


DOI: 10.1111/ddg.14934

PMID: 36748846



4. Diagn Progn Res. 2023 Feb 7;7(1):2. doi: 10.1186/s41512-023-00141-5.


Development and internal validation of a diagnostic prediction model for 

psoriasis severity.


Liljendahl MS(1)(2), Loft N(3), Egeberg A(4), Skov L(3), Nguyen TL(5).


Author information:

(1)Department of Dermatology and Allergy, Herlev and Gentofte Hospital, 

University of Copenhagen, Gentofte Hospitalsvej 15, 2900, Hellerup, Denmark. 

mie.sylow.liljendahl@regionh.dk.

(2)Department of Dermatology and Venereology, Bispebjerg and Frederiksberg 

Hospital, University of Copenhagen, Copenhagen, Denmark. 

mie.sylow.liljendahl@regionh.dk.

(3)Department of Dermatology and Allergy, Herlev and Gentofte Hospital, 

University of Copenhagen, Gentofte Hospitalsvej 15, 2900, Hellerup, Denmark.

(4)Department of Dermatology and Venereology, Bispebjerg and Frederiksberg 

Hospital, University of Copenhagen, Copenhagen, Denmark.

(5)Department of Public Health, Section of Epidemiology, University of 

Copenhagen, Copenhagen, Denmark.


BACKGROUND: While administrative health records such as national registries may 

be useful data sources to study the epidemiology of psoriasis, they do not 

generally contain information on disease severity.

OBJECTIVES: To develop a diagnostic model to distinguish psoriasis severity 

based on administrative register data.

METHOD: We conducted a retrospective registry-based cohort study using the 

Danish Skin Cohort linked with the Danish national registries. We developed a 

diagnostic model using a gradient boosting machine learning technique to predict 

moderate-to-severe psoriasis. We performed an internal validation of the model 

by bootstrapping to account for any optimism.

RESULTS: Among 4016 adult psoriasis patients (55.8% women, mean age 59 years) 

included in this study, 1212 (30.2%) patients were identified as having 

moderate-to-severe psoriasis. The diagnostic prediction model yielded a 

bootstrap-corrected discrimination performance: c-statistic equal to 0.73 [95% 

CI: 0.71-0.74]. The internal validation by bootstrap correction showed no 

substantial optimism in the results with a c-statistic of 0.72 [95% CI: 

0.70-0.74]. A bootstrap-corrected slope of 1.10 [95% CI: 1.07-1.13] indicated a 

slight under-fitting.

CONCLUSION: Based on register data, we developed a gradient boosting diagnostic 

model returning acceptable prediction of patients with moderate-to-severe 

psoriasis.


© 2023. The Author(s).


DOI: 10.1186/s41512-023-00141-5

PMID: 36747306



5. Int Endod J. 2023 Feb 6. doi: 10.1111/iej.13902. Online ahead of print.


Prevalence of Apical Periodontitis in Patients with Autoimmune Diseases: A Case 

Control Study.


Allihaibi M(1)(2), Niazi S(1), Farzadi S(1), Austin R(3), Ideo F(4), Cotti E(4), 

Mannocci F(1).


Author information:

(1)Department of Endodontics, Centre for Oral, Clinical and Translational 

Sciences, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College 

London, London, UK.

(2)Department of Endodontics, Faculty of Dentistry, Taif University, Taif, Saudi 

Arabia.

(3)Department of Prosthodontics, Centre for Oral, Clinical and Translational 

Sciences, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College 

London, London, UK.

(4)Department of Conservative Dentistry and Endodontics, University of Cagliari, 

Cagliari, Italy.


AIM: The purpose of this case-control study was to compare the prevalence of 

Apical Periodontitis (AP) in patients affected by Autoimmune Disorders (AD) 

[Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA), and Psoriasis 

(Ps)] with the prevalence of AP in subjects without AD. The prevalences of AP in 

patients taking biologic medications, conventional medications and no medication 

were also compared.

METHODOLOGY: 89 patients (2,145 teeth) with AD were investigated and the control 

group included 89 patients (2,329 teeth) with no systemic diseases. Full dental 

panoramic tomograms were used to determine the periapical status of the teeth. 

Additional variables investigated included patient's socio-demographic 

characteristics, medications taken by AD patients, the Decayed, Missing, and 

Filled Teeth (DMFT) index. The chi-square test and logistic regression analysis 

were used to evaluate the correlation between AD and AP. P-values lower than 

0.05 were considered to be statistically significant.

RESULTS: The prevalence of AP was 89.9% in AD patients and 74.2% in control 

subjects (odds ratio [OR]=3.75, p=0.015). The DMFT score was found to be 

significantly higher in the AD group (p=0.004). Patients with RA had the highest 

risk of being affected by AP, whereas those with IBD had the lowest risk. 

Multiple binary logistic regression analysis indicated that the teeth of AD 

patients who were not taking any medication or were being treated with biologic 

Disease Modifying Anti-Rheumatic Drugs (bDMARDs) had a higher risk of being 

affected by AP than did the teeth of the control subjects (OR=1.42 and OR=2.03 

respectively; p=0.010). The teeth of patients taking conventional DMARDs 

(cDMARDs) were less affected by AP compared with those of patients taking 

bDMARDs.

CONCLUSIONS: Patients with AD, whether treated or not with biologic medications, 

showed a higher prevalence of AP than did those in the control group. The DMFT 

index score, which was higher in AD patients compared with controls was 

identified as a significant predictor of AP prevalence.


This article is protected by copyright. All rights reserved.


DOI: 10.1111/iej.13902

PMID: 36747086



6. Lancet. 2023 Feb 3:S0140-6736(23)00022-3. doi: 10.1016/S0140-6736(23)00022-3. 

Online ahead of print.


Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and 

SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, 

placebo-controlled, double-blind phase 3 trials.


Kimball AB(1), Jemec GBE(2), Alavi A(3), Reguiai Z(4), Gottlieb AB(5), Bechara 

FG(6), Paul C(7), Giamarellos Bourboulis EJ(8), Villani AP(9), Schwinn A(10), 

Ruëff F(11), Pillay Ramaya L(12), Reich A(13), Lobo I(14), Sinclair R(15), 

Passeron T(16), Martorell A(17), Mendes-Bastos P(18), Kokolakis G(19), Becherel 

PA(20), Wozniak MB(21), Martinez AL(22), Wei X(23), Uhlmann L(22), Passera 

A(22), Keefe D(24), Martin R(24), Field C(21), Chen L(24), Vandemeulebroecke 

M(22), Ravichandran S(24), Muscianisi E(24).


Author information:

(1)Harvard Medical School and Clinical Laboratory for Epidemiology and Applied 

Research in Skin, Department of Dermatology, Beth Israel Deaconess Medical 

Center, Boston, MA, USA. Electronic address: clears@bidmc.harvard.edu.

(2)Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.

(3)Department of Dermatology, Mayo Clinic, Rochester, MN, USA.

(4)Dermatology Department, Polyclinique Courlancy-Bezannes, Reims, France.

(5)Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, 

NY, USA.

(6)Department of Dermatology, Venereology and Allergology, Ruhr-University 

Bochum, Bochum, Germany.

(7)Department of Dermatology, INSERM Infinity, Toulouse University, Toulouse, 

France.

(8)4th Department of Internal Medicine, Medical School, National and 

Kapodistrian University of Athens, Athens, Greece.

(9)Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, 

Claude Bernard Lyon I University, Lyon, France.

(10)Beldio Research, Memmingen, Germany.

(11)Department of Dermatology and Allergy, University Hospital Ludwig Maximilian 

University of Munich, Munich, Germany.

(12)Department of Dermatology, Global Clinical Trials, Pretoria, South Africa.

(13)Department of Dermatology, Institute of Medical Sciences, Medical College of 

Rzeszow University, Rzeszów, Poland.

(14)Centro Hospitalar do Porto, Hospital de Santo Antonio Porto, Porto, 

Portugal.

(15)Sinclair Dermatology, Melbourne, VIC, Australia.

(16)Department of Dermatology Centre Hospitalier Universitaire de Nice, C3M, 

INSERM U1065, Côte d'Azur University, Nice, France.

(17)Department of Dermatology, Hospital de Manises, Valencia, Spain.

(18)Dermatology Centre, Hospital Companhia União Fabril Descobertas, Lisbon, 

Portugal.

(19)Psoriasis Research and Treatment Center, Department of Dermatology, 

Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate 

member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 

Germany.

(20)Department of Dermatology, Venereology and Allergology, Antony Private 

Hospital, Antony, France.

(21)Novartis Ireland, Dublin, Ireland.

(22)Novartis Pharma, Basel, Switzerland.

(23)Novartis Pharma Shanghai, Shanghai, China.

(24)Novartis Pharmaceuticals, East Hanover, NJ, USA.


BACKGROUND: Few therapeutic options are available for patients with 

moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of 

secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two 

randomised trials.

METHODS: SUNSHINE and SUNRISE were identical, multicentre, randomised, 

placebo-controlled, double-blind phase 3 trials done in 219 primary sites in 40 

countries. Patients aged 18 years old or older with the capacity to provide 

written informed consent and with moderate-to-severe hidradenitis suppurativa 

(defined as a total of ≥5 inflammatory lesions affecting ≥2 distinct anatomical 

areas) for at least 1 year were eligible for inclusion. Included patients also 

agreed to daily use of topical over-the-counter antiseptics on the areas 

affected by hidradenitis suppurativa lesions while on study treatment. Patients 

were excluded if they had 20 or more fistulae at baseline, had ongoing active 

conditions requiring treatment with prohibited medication (eg, systemic 

biological immunomodulating treatment, live vaccines, or other investigational 

treatments), or met other exclusion criteria. In both trials, patients were 

randomly assigned (1:1:1) by means of interactive response technology to receive 

subcutaneous secukinumab 300 mg every 2 weeks, subcutaneous secukinumab 300 mg 

every 4 weeks, or subcutaneous placebo all via a 2 mL prefilled syringe in a 

double-dummy method as per treatment assignment. The primary endpoint was the 

proportion of patients with a hidradenitis suppurativa clinical response, 

defined as a decrease in abscess and inflammatory nodule count by 50% or more 

with no increase in the number of abscesses or in the number of draining 

fistulae compared with baseline, at week 16, assessed in the overall population. 

Hidradenitis suppurativa clinical response was calculated based on the number of 

abscesses, inflammatory nodules, draining fistulae, total fistulae, and other 

lesions in the hidradenitis suppurativa affected areas. Safety was assessed by 

evaluating the presence of adverse events and serious adverse events according 

to common terminology criteria for adverse events, which were coded using 

Medical Dictionary for Regulatory Activities terminology. Both the SUNSHINE, 

NCT03713619, and SUNRISE, NCT03713632, trials are registered with 

ClinicalTrials.gov.

FINDINGS: Between Jan 31, 2019, and June 7, 2021, 676 patients were screened for 

inclusion in the SUNSHINE trial, of whom 541 (80%; 304 [56%] women and 237 [44%] 

men; mean age 36·1 years [SD 11·7]) were included in the analysis (181 [33%] in 

the secukinumab every 2 weeks group, 180 [33%] in the secukinumab every 4 weeks 

group, and 180 [33%] in the placebo group). Between the same recruitment dates, 

687 patients were screened for inclusion in the SUNRISE trial, of whom 543 (79%; 

306 [56%] women and 237 [44%] men; mean age 36·3 [11·4] years) were included in 

the analysis (180 [33%] in the secukinumab every 2 weeks group, 180 [33%] in the 

secukinumab every 4 weeks group, and 183 [34%] in the placebo group). In the 

SUNSHINE trial, significantly more patients in the secukinumab every 2 weeks 

group had a hidradenitis suppurativa clinical response (rounded average number 

of patients with response in 100 imputations, 81·5 [45%] of 181 patients) 

compared with the placebo group (60·7 [34%] of 180 patients; odds ratio 1·8 [95% 

CI 1·1-2·7]; p=0·0070). However, there was no significant difference between the 

number of patients in the secukinumab every 4 weeks group (75·2 [42%] of 180 

patients) and the placebo group (1·5 [1·0-2·3]; p=0·042). Compared with the 

placebo group (57·1 [31%] of 183 patients), significantly more patients in the 

secukinumab every 2 weeks group (76·2 [42%] of 180 patients; 1·6 [1·1-2·6]; 

p=0·015) and the secukinumab every 4 weeks group (83·1 [46%] of 180 patients; 

1·9 [1·2-3·0]; p=0·0022) had a hidradenitis suppurativa clinical response in the 

SUNRISE trial. Patient responses were sustained up to the end of the trials at 

week 52. The most common adverse event by preferred term up to week 16 was 

headache in both the SUNSHINE (17 [9%] patients in the secukinumab every 2 weeks 

group, 20 [11%] in the secukinumab every 4 weeks group, and 14 [8%] in the 

placebo group) and SUNRISE (21 [12%] patients in the secukinumab every 2 weeks 

group, 17 [9%] in the secukinumab every 4 weeks group, and 15 [8%] in the 

placebo group) trials. No study-related deaths were reported up to week 16. The 

safety profile of secukinumab in both trials was consistent with that previously 

reported, with no new or unexpected safety findings detected.

INTERPRETATION: When given every 2 weeks, secukinumab was clinically effective 

at rapidly improving signs and symptoms of hidradenitis suppurativa with a 

favourable safety profile and with sustained response up to 52 weeks of 

treatment.

FUNDING: Novartis Pharma.


Copyright © 2023 Elsevier Ltd. All rights reserved.


DOI: 10.1016/S0140-6736(23)00022-3

PMID: 36746171


Conflict of interest statement: Declaration of interests ABK reports grants from 

AbbVie, Anapyts Bio, Aristea, Bristol Myers Squibb, ChemoCentryx, Eli Lilly, 

Incyte, Janssen, Moonlake, Novartis, Pfizer, UCB, and Sonoma Bio and fellowship 

funding from AbbVie and Janssen paid to her institution; royalties from BIDMC; 

consulting fees from AbbVie, Alumis, Bayer, Bristol Myers Squibb, 

Boehringer-Ingelheim, Eli Lilly, FIDE, Novartis, Moonlake, Janssen, Pfizer, 

Priovant, Sonoma Bio, Sanofi, Target RWE, UCB, and Ventyx; stock in Ventyx; 

serving on advisory boards for Target RWE; serving as an advisory council member 

to the National Institute of Health Director; and serves on the board of 

directors of Almirall. GBEJ reports grants from AbbVie, Boehringer-Ingelheim, 

CSL Behring, Regeneron, InflaRx, Novartis, LEO Foundation, and UCB, paid to 

their institution, and honoraria for advisory board meetings from Coloplast, 

Union Therapeutics, Toosonix, Boehringer-Ingelheim, Kymera, Sanofi, Viela Bio, 

ChemoCentryx, LEO Pharma, Afyx, Incyte, InflaRx, Janssen Cilag, Novartis, and 

UCB. AA reports consulting fees from AbbVie, Boehringer-Ingelheim, InflaRx, and 

UCB, paid to their institution, and consulting fees from Novartis, AbbVie, and 

Boehringer-Ingelheim. ZR reports consulting fees and honoraria from AbbVie, 

Amgen, Janssen-Cilag, Novartis, UCB, Sanofi; consulting fees from Celltrion; 

personal fees for attending meetings or for travel from AbbVie, Janssen-Cilag, 

Novartis, UCB, and Sanofi; and payment for expert testimony from AbbVie, Amgen, 

Celltrion, Janssen-Cilag, Novartis, and UCB. ABG reports research and 

educational grants from AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun 

Pharma, BMS, and UCB Pharma, paid to their institution; consulting fees from 

Amgen, AnaptysBio, Avotres Therapeutics, Boehringer-Ingelheim, Bristol Myers 

Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB 

Pharma, and DiCE Therapeutics; honoraria as an advisory board member, or 

non-promotional speaker from Amgen, AnaptysBio, Avotres Therapeutics, 

Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, 

Novartis, Pfizer, Sanofi, Sun Pharma, and UCB Pharma; is a president of 

International Dermatology Outcome Measures; and holds stock options in XBiotech, 

for work on a rheumatoid arthritis project. FGB reports consulting fees from 

AbbVie, Novartis, and UCB; honoraria and support for attending meetings or 

travel from AbbVie, Janssen Cilag, Novartis, and UCB; and served on a Data 

Safety Monitoring Board or Advisory Board for AbbVie, Boehringer-Ingelheim, 

Janssen Cilag, Novartis, UCB, Incyte, and Moonlake. CP reports consulting fees 

from Almirall, AbbVie, Amgen, BMS, Boehringer-Ingelheim, Celgene, GSK, Janssen, 

LEO Pharma, Eli Lilly, Merck, Novartis, Pfizer, Sanofi, and UCB and served on a 

Data Safety Monitoring Board or Advisory Board for IQVIA. EJGB reports grants 

from Horizon 2020 ImmunoSep and RISKinCOVID, Horizon Health EPIC-CROWN-2, Sobi, 

bioMérieux, MSD, Abbott, Novartis, UCB, and AbbVie, paid to their institution, 

and consulting fees from Sobi, Pfizer, Abbott, ThermoFisher, and Menarini. APV 

reports consulting fees from Janssen-Cilag; payment or honoraria from AbbVie, 

Almirall, BMS, Janssen-Cilag, Leo Pharma, Eli Lilly, MSD, Novartis, and UCB; and 

support for attending meetings or travel from Janssen-Cilag and UCB. AS reports 

consulting fees from Regeneron, Novartis, and AbbVie, paid to their institution; 

payment or honoraria from AbbVie, Novartis, Regeneron, Sanofi; support for 

attending meetings or travel from AbbVie, Janssen-Cilag, Novartis, and Sanofi; 

and fees for participation on a Data Safety Monitoring Board or Advisory Board 

from AbbVie, Novartis, and Sanofi. FR reports grants from ALK-Abelló, 

Allergopharma, Blueprint Medicines, Mylan, Novartis, and ThermoFisher; served on 

a Data Safety Monitoring Board or Advisory Board for ALK-Abelló, 

Boehringer-Ingelheim, Blueprint Medicines, Leo Pharma, and UCB; and is an active 

member of the German Association of Allergy and Clinical Immunology. AR and his 

institution received grants from AbbVie, Alvotech, Amgen, AnaptysBio, Argenx, 

Biothera, Bristol Myers Squibb, Celgene, Celltrion, Dermira, Galderma, Inflarx, 

Janssen, Kiniksa, Kymab, Leo Pharma, Novartis, Pfizer, Trevi Therapeutics, and 

UCB; payment or honoraria from Chema Rzeszow, Eli Lilly, Leo Pharma, Novartis, 

Sandoz, and Takeda; and served on a Data Safety Monitoring Board or Advisory 

Board for AbbVie, Galderma, Sandoz, and Sanofi Aventis. IL reports payment or 

honoraria from Novartis and support for attending meetings or travel from 

Sanofi. TP reporfts grants from Almirall, Incyte, and Pfizer, paid to their 

institution, and consulting fees from AbbVie, Almirall, Bristol Myers Squibb, 

Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, and UCB. AM reports 

consulting fees from AbbVie, Boehringer-Ingelheim, Jansen, Eli Lilly, Novartis, 

Novo Nordisk, Sandoz, and UCB; payment for expert testimony or honoraria from 

AbbVie, Boehringer-Ingelheim, Jansen, Eli Lilly, Novartis, Novo Nordisk, Sandoz, 

and UCB; and support for attending meetings or travel from AbbVie, Novartis, 

Jansen, and UCB. PM-B reports consulting fees from AbbVie, Almirall, Eli Lilly, 

Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi; payment or honoraria from 

AbbVie, Almirall, Janssen, LEO Pharma, Eli Lilly, Novartis, Organon, Pfizer, 

Sanofi, and Viatris; support for attending meetings or travel from AbbVie, 

Almirall, Janssen, LEO Pharma, Eli Lilly, Novartis, and Sanofi; and served on a 

Data Safety Monitoring Board or Advisory Board for AbbVie, Janssen, LEO Pharma, 

Eli Lilly, Novartis, Pfizer, and Sanofi. GK reports consulting fees from Bayer; 

payment or honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, 

Basilea Pharmaceutica, Biogen IDEC, Boehringer-Ingelheim, Bristol Myers Squibb, 

Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, 

Parexel, Pfizer, and UCB; support for attending meetings or travel from AbbVie, 

Abbott, Amgen, Basilea Pharmaceutica, Celgene, Janssen-Cilag, LEO Pharma, MSD, 

Novartis, Pfizer, Sanofi, and UCB; and served on a Data Safety Monitoring Board 

or Advisory Board for AbbVie, Abbott, Amgen, Basilea, Bayer, 

Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, LEO Pharma, 

Eli Lilly, Novartis, and UCB. P-AB reports consulting fees from Novartis, 

AbbVie, Pfizer, and UCB pharma; payment or honoraria from Novartis and AbbVie; 

support for attending meetings or travel from Novartis; and served on a Data 

Safety Monitoring Board or Advisory Board for Novartis. MBW, ALM, XW, LU, AP, 

DK, RM, CF, LC, MV, SR, and EM are employees of Novartis and hold company stock. 

RS is Director and Founder of Samson Medical, has participated in pharmaceutical 

advisory boards for Eli Lilly and Company, Pfizer, and Leo Pharmaceutical, has 

participated in speaker bureaus for AbbVie, Novartis, and Pfizer, and has acted 

as a principal investigator in clinical trials for AbbVie, Aerotech, Akesobio, 

Amgen, Arcutis, Arena, Ascend AstraZeneca, Bayer, Biotherapeutics 

Boehringer-Ingelheim, Bristol-Myer Squibb, Celgene, Coherus BioSciences, 

Connect, Demira, Eli Lilly, Galderma, GlaxoSmithKline, F Hoffman–La Roche, 

Janssen, MedImmune, Merck, Merck Sharpe & Dohme, Novartis, Oncobiologics, 

Pfizer, Principia, Regeneron, Roche, Reistone Biopharma, Samson Clinical, 

Sanofi-Genzyme, Sun Pharma UCB, Valeant, and Zai Labs. RS is President of the 

Australasian Hair and Wool Research Society, and Vice President of the 

International Society of Dermatology and The International Academy of 

Dermatology. LPR declares no competing interests.



7. Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093/bjd/ljac132. Online ahead of 

print.


Factors associated with depression, anxiety and severe mental illness among 

adults with atopic eczema or psoriasis: a systematic review and meta-analysis.


Adesanya EI(1), Matthewman J(1), Schonmann Y(2)(3), Hayes JF(4), Henderson A(1), 

Mathur R(1), Mulick AR(1), Smith CH(5), Langan SM(1)(6), Mansfield KE(1).


Author information:

(1)Department of Non-Communicable Disease Epidemiology, London School of Hygiene 

& Tropical Medicine, London, UK.

(2)Siaal Research Center for Family Medicine and Primary Care, Faculty of Health 

Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

(3)Department of Quality Measurements and Research, Clalit Health Services, Tel 

Aviv, Israel.

(4)Division of Psychiatry, University College London, London, UK.

(5)St John's Institute of Dermatology, Guys and St Thomas' Foundation Trust and 

King's College London, London, UK.

(6)Health Data Research UK, London, UK.


BACKGROUND: Evidence suggests an association between atopic eczema (AE) or 

psoriasis and mental illness; however, the factors associated with mental 

illness are unclear.

OBJECTIVES: To synthesize and evaluate all available evidence on factors 

associated with depression, anxiety and severe mental illness (SMI) among adults 

with AE or psoriasis.

METHODS: We searched electronic databases, grey literature databases and 

clinical trial registries from inception to February 2022 for studies of adults 

with AE or psoriasis. Eligible studies included randomized controlled trials 

(RCTs), cohort, cross-sectional or case-control studies where effect estimates 

of factors associated with depression, anxiety or SMI were reported. We did not 

apply language or geographical restrictions. We assessed risk of bias using the 

Quality in Prognosis Studies tool. We synthesized results narratively, and if at 

least two studies were sufficiently homogeneous, we pooled effect estimates in a 

random effects meta-analysis.

RESULTS: We included 21 studies (11 observational, 10 RCTs). No observational 

studies in AE fulfilled our eligibility criteria. Observational studies in 

people with psoriasis mostly investigated factors associated with depression or 

anxiety - one cross-sectional study investigated factors associated with 

schizophrenia. Pooled effect estimates suggest that female sex and psoriatic 

arthritis were associated with depression [female sex: odds ratio (OR) 1.62, 95% 

confidence interval (CI) 1.09-2.40, 95% prediction intervals (PIs) 0.62-4.23, I2 

= 24.90%, τ2 = 0.05; psoriatic arthritis: OR 2.26, 95% CI 1.56-3.25, 95% PI 

0.21-24.23, I2 = 0.00%, τ2 = 0.00] and anxiety (female sex: OR 2.59, 95% CI 

1.32-5.07, 95% PI 0.00-3956.27, I2 = 61.90%, τ2 = 0.22; psoriatic arthritis: OR 

1.98, 95% CI 1.33-2.94, I2 = 0.00%, τ2 = 0.00). Moderate/severe psoriasis was 

associated with anxiety (OR 1.14, 95% CI 1.05-1.25, I2 0.00%, τ2 = 0.00), but 

not depression. Evidence from RCTs suggested that adults with AE or psoriasis 

given placebo had higher depression and anxiety scores compared with comparators 

given targeted treatment (e.g. biologic agents).

CONCLUSIONS: Our review highlights limited existing research on factors 

associated with depression, anxiety and SMI in adults with AE or psoriasis. 

Observational evidence on factors associated with depression or anxiety in 

people with psoriasis was conflicting or from single studies, but some 

identified factors were consistent with those in the general population. 

Evidence on factors associated with SMIs in people with AE or psoriasis was 

particularly limited. Evidence from RCTs suggested that AE and psoriasis treated 

with placebo was associated with higher depression and anxiety scores compared 

with skin disease treated with targeted therapy; however, follow-up was limited. 

Therefore, long-term effects on mental health are unclear.


© The Author(s) 2022. Published by Oxford University Press on behalf of British 

Association of Dermatologists. This is an Open Access article distributed under 

the terms of the Creative Commons Attribution License 

(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted 

reuse, distribution, and reproduction in any medium, provided the original work 

is properly cited.


DOI: 10.1093/bjd/ljac132

PMID: 36745557


Conflict of interest statement: Conflicts of interest J.F.H. has received 

consultancy fees from Wellcome Trust and juli Health. R.M. has received 

consultancy fees from AMGEN.



8. Am J Physiol Cell Physiol. 2023 Feb 6. doi: 10.1152/ajpcell.00269.2022. Online 

ahead of print.


The role of vasoactive peptides in skin homeostasis - focus on adiponectin and 

the kallikrein-kinin system.


Souza-Silva IM(1), Steckelings UM(1), Assersen KB(1)(2).


Author information:

(1)Dept. of Cardiovascular and Renal Research, Institute for Molecular Medicine, 

University of Southern Denmark, Odense, Denmark.

(2)Dept. of Dermatology, Odense University Hospital, Odense, Denmark.


Vasoactive peptides often serve a multitude of functions aside from their direct 

effects on vasodynamics. This article will review the existing literature on two 

vasoactive peptides and their involvement in skin homeostasis: adiponectin and - 

as main representative of the kallikrein-kinin-system - bradykinin. Adiponectin 

is the most abundantly expressed adipokine in the human organism, where it is 

mainly localized in fat depots including subcutaneous adipose tissue, from where 

adiponectin can exert paracrine effects. The involvement of adiponectin in skin 

homeostasis is supported by a number of studies reporting effects of adiponectin 

in isolated human keratinocytes, sebocytes, fibroblasts, melanocytes and immune 

cells. Regarding skin pathology, the potential involvement of adiponectin in 

psoriasis, atopic dermatitis, scleroderma, keloid and melanogenesis is discussed 

in this article. The kallikrein-kinin-system is composed of a variety of enzymes 

and peptides, most of which have been identified to be expressed in skin. This 

also includes expression of bradykinin receptors on most skin cells. Bradykinin 

is one of very few hormones that is targeted by a treatment in routine clinical 

use in dermatology - in this case for the treatment of hereditary angioedema. 

Potential involvement of bradykinin in wound healing, psoriasis and melanoma is 

further discussed in this article. This review concludes with a call for 

additional preclinical and clinical studies to further explore the therapeutic 

potential of adiponectin supplementation (for psoriasis, atopic dermatitis, 

wound healing, scleroderma and keloid) or pharmacological interference with the 

kallikrein-kinin-system (for wound healing, psoriasis and melanoma).


DOI: 10.1152/ajpcell.00269.2022

PMID: 36745527



9. Australas J Dermatol. 2023 Feb 6. doi: 10.1111/ajd.13998. Online ahead of print.


Three cases of oral mucosal tuberculosis in patients on tumour-necrosis-factor-α 

blockers.


Nico MMS(1), Fanciozi AB(1), da Costa ÁF(2), Lourenço SV(3).


Author information:

(1)Department of Dermatology, Medical School, University of São Paulo, São 

Paulo, Brazil.

(2)Department of Infectious Diseases, Medical School, University of São Paulo, 

São Paulo, Brazil.

(3)Department of Pathology, Dental School, University of São Paulo, São Paulo, 

Brazil.


We present three cases of oral mucosal lesions caused by Mycobacterium 

tuberculosis in patients treated with anti-tumour necrosis factor-α for 

psoriasis or rheumatoid arthritis. Diagnosis of oral mucosal tuberculosis was 

not easily established in any of the cases. A comparison between these cases and 

other previously described forms of oral mucosal tuberculosis is presented.


© 2023 Australasian College of Dermatologists.


DOI: 10.1111/ajd.13998

PMID: 36745517



10. J Drugs Dermatol. 2023 Feb 1;22(2):SF344607s3-SF344607s14.


Supplement Individual Article: The Importance of a Healthy Skin Barrier From the 

Cradle to the Grave Using Ceramide-Containing Cleansers and Moisturizers: A 

Review and Consensus.


Schachner L, Alexis A, Andriessen A, Baldwin H, Cork M, Kirsner R, Woolery-Lloyd 

H.


INTRODUCTION: Inflammatory skin disorders compromise skin barrier health. Early 

and daily skincare use aims to maintain a life-long healthy skin barrier. 

Racial/ethnic and age variations in skin barrier properties, cultural 

differences, and clinical presentation of the inflammatory skin disorder 

influence the choice of treatment and skin care. Ceramide-containing skin care 

may play a role in restoring and maintaining a healthy skin barrier.

METHODS: A panel of 6 dermatologists met to develop consensus statements based 

on their 8 previous publications on promoting skin barrier health throughout 

life using ceramide-containing skin care. The publications covered skin barrier 

integrity in the newborn and infant, and the role of the skin barrier in 

mitigating atopic dermatitis (AD); racial/ethnic variations in the skin barrier 

and implications for skin care; the role of the skin barrier in inflammatory 

skin conditions including acne, AD and psoriasis in skin of color (SOC) 

populations; skin barrier integrity in patients with rosacea; and xerosis in 

patients with diabetes mellitus. The panel synthesized the 8 publications, 

selected information from a literature review, and their expert opinions and 

experiences to create the statements. The consensus was reached through a 

modified Delphi method where the panel met face-to-face and followed up 

virtually.

RESULTS: The panel adopted 6 consensus statements highlighting the importance of 

skin care in restoring/maintaining a healthy skin barrier in the populations 

mentioned above. Skin care suited to this role is gentle, has near-physiologic 

pH, is pleasant to use, and contains ceramides. This type of skin care can 

promote a healthy skin barrier and attenuate or delay inflammatory skin 

conditions.

CONCLUSIONS: Adjunctive daily skin care throughout life promotes a healthy skin 

barrier and is beneficial in managing various inflammatory skin disorders in all 

populations. However, when choosing optimal treatment and skin care, physicians 

should consider variations in age, skin properties, presentation of the 

condition, and cultural differences. J Drugs Dermatol. 2023;22:2(Suppl 1):s3-14.


PMID: 36745380


Copyright © 2018 Medical Center MP Template - All Rights Reserved.

  • Contact Us
  • Archive
  • Potential Fellows